OBJECTIVES: The purpose of this study was to determine the effect of release from prison and subsequent re-incarceration on the viral loads of HIV-infected individuals receiving highly active antiretroviral therapy (HAART). METHODS: Fifteen re-incarcerated HIV-infected prisoners on HAART were identified from a retrospective cohort of HIV-infected prison inmates released from January 1, 1997, to August 31, 1999. The re-incarcerated prisoners were matched (1:2) to 30 HIV-infected incarcerated prisoners on HAART who remained incarcerated during the re-incarcerated participants' release time period. The outcomes measured were plasma HIV RNA levels, CD4+ lymphocyte counts, percentage of re-incarcerated and incarcerated participants with plasma HIV RNA levels <400 copies/mL, and the median change in plasma HIV RNA levels of the re-incarcerated and incarcerated participants at the end of the study. RESULTS: At the beginning of the study, 8/15 re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 15/30 incarcerated participants. At the end of the study, only three of those eight re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 14/15 incarcerated participants (p=0.0086). The median change in plasma HIV RNA levels of the re-incarcerated participants was 1.29 log10 copies/mL (interquartile range 0.04 to 1.70), compared with -0.03 log10 copies/mL (interquartile range -0.65 to 0.09) in the incarcerated participants (p=0.0183). CONCLUSIONS: Release from prison was associated with a deleterious effect on virological and immunological outcomes. These data suggest that comprehensive discharge planning efforts are required to make certain that HIV-infected inmates receive access to quality care following incarceration.
OBJECTIVES: The purpose of this study was to determine the effect of release from prison and subsequent re-incarceration on the viral loads of HIV-infected individuals receiving highly active antiretroviral therapy (HAART). METHODS: Fifteen re-incarcerated HIV-infected prisoners on HAART were identified from a retrospective cohort of HIV-infected prison inmates released from January 1, 1997, to August 31, 1999. The re-incarcerated prisoners were matched (1:2) to 30 HIV-infected incarcerated prisoners on HAART who remained incarcerated during the re-incarcerated participants' release time period. The outcomes measured were plasma HIV RNA levels, CD4+ lymphocyte counts, percentage of re-incarcerated and incarcerated participants with plasma HIV RNA levels <400 copies/mL, and the median change in plasma HIV RNA levels of the re-incarcerated and incarcerated participants at the end of the study. RESULTS: At the beginning of the study, 8/15 re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 15/30 incarcerated participants. At the end of the study, only three of those eight re-incarcerated participants had plasma HIV RNA levels <400 copies/mL, compared with 14/15 incarcerated participants (p=0.0086). The median change in plasma HIV RNA levels of the re-incarcerated participants was 1.29 log10 copies/mL (interquartile range 0.04 to 1.70), compared with -0.03 log10 copies/mL (interquartile range -0.65 to 0.09) in the incarcerated participants (p=0.0183). CONCLUSIONS: Release from prison was associated with a deleterious effect on virological and immunological outcomes. These data suggest that comprehensive discharge planning efforts are required to make certain that HIV-infected inmates receive access to quality care following incarceration.
Authors: H Liu; C E Golin; L G Miller; R D Hays; C K Beck; S Sanandaji; J Christian; T Maldonado; D Duran; A H Kaplan; N S Wenger Journal: Ann Intern Med Date: 2001-05-15 Impact factor: 25.391
Authors: R M Malow; S M Baker; N Klimas; M H Antoni; N Schneiderman; F J Penedo; D Ziskind; B Page; R McMahon; S McPherson Journal: Psychiatr Serv Date: 1998-08 Impact factor: 3.084
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Anne Spaulding; Becky Stephenson; Grace Macalino; William Ruby; Jennifer G Clarke; Timothy P Flanigan Journal: Clin Infect Dis Date: 2002-07-03 Impact factor: 9.079
Authors: Amy J Harzke; Jacques G Baillargeon; Sandi L Pruitt; John S Pulvino; David P Paar; Michael F Kelley Journal: J Urban Health Date: 2010-05 Impact factor: 3.671
Authors: Jacques Baillargeon; Thomas P Giordano; Amy Jo Harzke; Anne C Spaulding; Z Helen Wu; James J Grady; Gwen Baillargeon; David P Paar Journal: AIDS Patient Care STDS Date: 2010-06 Impact factor: 5.078
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Turquoise Sidibe; Carol Golin; Kea Turner; Niasha Fray; Cathie Fogel; Patrick Flynn; Michele Gould; Kevin Knight; David Wohl Journal: J Assoc Nurses AIDS Care Date: 2015-05-19 Impact factor: 1.354
Authors: Emily A Wang; Kathleen A McGinnis; Jessica B Long; Kathleen M Akgün; E Jennifer Edelman; David Rimland; Karen H Wang; Amy C Justice; David A Fiellin Journal: Am J Addict Date: 2015-02-06